About
LicensingInsightsBioLink WeeklyJob BoardNews中文Contact Us
Princeton, NJ — US-China Biopharma

Catalyzing US‑China
Biotech & Pharma Partnerships

BioRich International connects leading pharmaceutical companies and biotech innovators across the US-China corridor — facilitating licensing deals, capital connections, and R&D collaboration.

Explore Our ServicesRead BioLink Weekly
0+
Chinese Clients
0+
Projects
0+
MNC Connections
0+
Years of Experience
Our Services

Comprehensive Support Across the Deal Lifecycle

Licensing Deals

Out-licensing & in-licensing facilitation between Chinese biotechs and global pharma. 250+ clients, 400+ projects.

Learn more

Capital & Talent

We connect biopharma companies with pre-screened US venture capital and provide executive and scientific recruitment support — drawing on one of the most extensive personal networks in US-China biopharma to place the right people at the right time.

Learn more

CRO/CDMO Matching

Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape — and beyond — to match clients with partners whose capabilities align with their program requirements.

Learn more

Market Research

Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports, combined with BioLink Weekly, provide the depth and currency needed to make confident strategic decisions.

Learn more
About BioRich

A Trusted Partner at the
Intersection of East and West

Founded by John Xu, MD, MBA, MS — with over 30 years of experience at Bristol Myers Squibb, Wyeth, WuXi AppTec, and CrownBio — BioRich International operates at the nexus of US and Chinese biopharma. We bridge the information, relationship, and cultural gaps that prevent high-potential deals from closing.

Our network encompasses 250+ Chinese biotech clients, direct relationships with BD&L leadership at 25+ multinational corporations, and active engagement with more than 10 US venture capital firms.

Meet our leadership
"

The biggest obstacle to deal-making is not interest or capital — it is information asymmetry. BioLink Weekly exists to close that gap.

John Xu, MD, MBA, MS

Founder & President, BioRich International

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers

View all issues →
Issue 26October 6, 2026

Novartis Commits Up to ~$7.8B for Abogen's China-Origin mRNA-Encoded T-Cell Engager as Merck Pays $400M Upfront for SciBrunch's Preclinical KRAS G12D Inhibitor - China-Out Reaches Worldwide Rights and Platform Modalities

Novartis agreed on October 2 to pay Suzhou-based Abogen $575M upfront - and up to roughly $7.8B in total - for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune disease, days after Merck paid $400M upfront for Shanghai-based SciBrunch's preclinical KRAS G12D inhibitor.

Read issue
Issue 25October 1, 2026

Novo Nordisk Bets Up to $2.6B on Hengrui's China-Origin Once-Weekly Oral Obesity Pill as AstraZeneca Puts $2B into Summit to Expand the China-Origin Ivonescimab Franchise - a Single Day Reshapes the US-China Deal Map Around Obesity and PD-1/VEGF

Novo Nordisk agreed on September 29 to pay Hengrui $300M upfront and up to $2.6B for ex-Greater China rights to HRS-1596, a Phase 1-ready once-weekly oral GLP-1/GIP pill - and the same day AstraZeneca took a $2B preferred-stock stake (rights to ~12% of Summit) to build ivonescimab, Akeso's China-origin PD-1/VEGF bispecific, into ADC combinations.

Read issue
Issue 24September 22, 2026

GSK Bets Up to $750M on Chimagen's China-Origin Trispecific T-Cell Engager for Multiple Myeloma as Washington Signals the China Licensing Door Stays Open - the U.S. Treasury Reportedly Drafts Rules to Preserve Pharma-China Deals and Chinese Biopharma Stocks Jump 6-8%

GSK agreed to pay up to $750M for a potential best-in-class trispecific T-cell engager for multiple myeloma from China's Chimagen Biosciences - its second Chimagen deal - even as Reuters reported the U.S. Treasury is drafting rules that would let American drugmakers keep licensing most Chinese assets, sending Akeso, Innovent, CSPC and Sino Biopharmaceutical up 6-8% in Hong Kong.

Read issue

Ready to Explore a Partnership?

Whether you are seeking a licensing partner, an R&D collaborator, or strategic intelligence on the China market, we are ready to help.

Get in Touch